|
|
Volumn 59, Issue 3 S, 1987, Pages 617-619
|
|
Use of interferon in the treatment of ovarian cancer as a single agent and in combination with cytotoxic drugs
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ALPHA INTERFERON;
ALPHA2B INTERFERON;
ALPHAN1 INTERFERON;
DOXORUBICIN;
INTERFERON;
RECOMBINANT ALPHA INTERFERON;
RECOMBINANT ALPHA2B INTERFERON;
ADVERSE DRUG REACTION;
BLOOD AND HEMOPOIETIC SYSTEM;
CANCER CHEMOTHERAPY;
CANCER COMBINATION CHEMOTHERAPY;
CANCER IMMUNOTHERAPY;
CARDIOTOXICITY;
CLINICAL ARTICLE;
CLINICAL TRIAL;
DRUG EFFICACY;
DRUG POTENTIATION;
DRUG THERAPY;
ENDOCRINE SYSTEM;
FEMALE GENITAL SYSTEM;
HEART;
HUMAN;
INTOXICATION;
INTRAPERITONEAL DRUG ADMINISTRATION;
INTRAVENOUS DRUG ADMINISTRATION;
INTRON;
LEUKOPENIA;
OVARY CANCER;
PHASE 1 CLINICAL TRIAL;
PHASE 2 CLINICAL TRIAL;
PRIORITY JOURNAL;
SUBCUTANEOUS DRUG ADMINISTRATION;
THERAPY;
THROMBOCYTOPENIA;
TOXICITY;
TUMOR VOLUME;
ANTINEOPLASTIC AGENTS;
DRUG EVALUATION;
DRUG THERAPY, COMBINATION;
FEMALE;
HUMAN;
INJECTIONS, INTRAPERITONEAL;
INTERFERON TYPE I;
OVARIAN NEOPLASMS;
TUMOR STEM CELL ASSAY;
|
|
EID: 0023094826
PISSN: 0008543X
EISSN: 10970142
Source Type: Journal
DOI: 10.1002/1097-0142(19870201)59:3+<617::AID-CNCR2820591308>3.0.CO;2-P Document Type: Article |
|
Times cited : (22)
|
|
References (11)
|
